Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients.
Invasive fungal infections are a major cause of morbidity and mortality in children with hematological malignancies and those undergoing allogeneic hematopoietic stem-cell transplantation (HSCT). Although several new antifungal compounds recently became available, some are not yet approved for the use in the pediatric population. Among the new class of echinocandins, micafungin has been licensed in Europe and Japan for children including neonates. Because micafungin is well tolerated and exhibits few clinical relevant drug-drug interactions, the compound is of particular interest for prophylaxis and treatment of invasive mycoses in pediatric patients with cancer or following allogeneic HSCT. This review will focus on the currently available pediatric data of micafungin with emphasis on pharmacokinetics, efficacy, and safety.
Lehrnbecher
Thomas
T
Pediatric Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany. thomas.lehrnbecher@kgu.de
Groll
Andreas H
AH
D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000633:toxicity; D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions; D054714:Echinocandins / Q000493:pharmacokinetics* / Q000633:toxicity; D019337:Hematologic Neoplasms / Q000150:complications; D006801:Humans; D055666:Lipopeptides / Q000493:pharmacokinetics* / Q000633:toxicity; D000077551:Micafungin; D009181:Mycoses / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin